TNFRSF10B and neoplasm: Importantly, besides avoiding immunosuppression, an effective DR5 agonist must also drive superior receptor clustering to eliminate both low and high DR5 expressing tumor cell in heterogeneous solid tumors (Ashkenazi, 2015).